Sage Journals: Discover world-class research

Abstract

Introduction: Clinical evidence indicates that acetylcholinesterase inhibitors (AChEIs) are not efficacious to treat frontotemporal lobar degeneration (FTLD). The British Association for Psychopharmacology recommends avoiding the use of AChEI and memantine in patients with FTLD. Methods: Cross-sectional design using 1092 cases with Alzheimer’s disease (AD) and 64 cases with FTLD registered by the Registry of Dementias of Girona. Bivariate analyses were performed, and binary logistic regressions were used to detect variables associated with antidementia drugs consumption. Results: The AChEIs were consumed by 57.6% and 42.2% of the patients with AD and FTLD, respectively. Memantine was used by 17.2% and 10.9% of patients with AD and FTLD, respectively. Binary logistic regressions yielded no associations with antidementia drugs consumption. Conclusions: There is a discrepancy regarding clinical practice and the recommendations based upon clinical evidence. The increased central nervous system drug use detected in FTLD requires multicentric studies aiming at finding the best means to treat these patients.

Keywords

Alzheimer’s disease frontotemporal dementia donepezil memantine galantamine rivastigmine treatment

Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease presenting with dementia. In most of the cases, the initial symptom is a mild cognitive impairment, caused by an increasing number of neurofibrillary lesions in the cortical transentorhinal region, the hippocampus, and in the limbic areas. As the disease advances, these lesions spread through the cerebral cortex.^1
–3 Neuropathologically, AD is characterized by the presence of β-amyloid (Aβ) extracellular deposits in neuritic plaques, and neurofibrillary alterations that include intracellular deposits of hyperphosphorilated tau protein in neurofibrillary tangles, dystrophic neurites, and neuropile threads.⁴

Frontotemporal lobar degeneration (FTLD), formerly known as Pick’s disease, constitutes 5% of the cases of dementia in autopsy series.⁵ Frontotemporal lobar degeneration include a group of heterogeneous neurodegenerative diseases, both regarding clinical presentation and histopathologic and genetic characteristics.^6,7 Clinical manifestations appear insidiously, and with the evolution of the disease, diverse characteristics of the personality deteriorate, depending on which prefrontal areas are affected.^8,9 Neuropathologically, the brain shows atrophy of frontal and temporal lobes, and abnormal protein aggregates in the neurons or the glia.¹⁰

Management of AD involves preventing vascular risk factors and symptomatic treatment with acetylcholinesterase inhibitors (AChEIs) and memantine, an uncompetitive N-methyl-d-aspartate receptor antagonist. These drugs provide subtle but significant benefits to help control cognitive symptoms, activities of daily living, and behavior disorders.¹¹ The AChEIs have been evaluated in a wide variety of neurodegenerative brain diseases, but clinical evidence reveals that they are only useful for treating AD, dementia with Lewy bodies, and Parkinson’s disease dementia.¹² Moreover, the British Association for Pharmacology suggests using AChEI in mild/moderate stages of AD and using memantine only in moderate/severe stages. They also state that both AChEI and memantine are ineffective to treat FTLD and recommend avoiding its use to prevent possible side effects, such as increased agitation.¹³

Despite the evidence-based clinical practices guidelines, clinical experience suggests that a high percentage of patients with FTLD are treated with AChEI and/or memantine. The main aim of this study was to describe the use of central nervous system (CNS) drugs in patients with AD and FTLD and to detect the main variables associated with the use of AChEI and memantine in patients with FTLD. Our study used the data collected from 2007 to 2009 by an epidemiological surveillance system focused on dementia. We combined this information with the information obtained from a drug prescription database.

Methods

Design, Geographical Area of Reference, and Study Population

This study used a cross-sectional design and was based on data from the cases registered by Registry of Dementias of Girona (ReDeGi) from 2007 to 2009, which was approved by the Review Board of the Institut d’Assistència Sanitària. The ReDeGi registers demographic and clinical data of all the new dementia cases diagnosed in the hospitals of the public health care system of the Health Region of Girona (HRG). The HRG is located in the North-East of Catalunya, which is, in turn, in the North-East part of Spain. It has an area of 5517 km², a population of 737 344 inhabitants (according to the Citizens Municipal Registry 2010), and a population density of 133.6 inhabitants/km².

Registry Procedure and Registered Variables

The ReDeGi registers all the incident cases of dementia diagnosed in the 7 hospitals belonging to the HRG, using standardized criteria for case definition, and following the guidelines proposed by the Center for Disease Control and Prevention for a surveillance system.¹⁴ The methodological principles and the functional structure of the ReDeGi have been previously described.^15
–17 All diagnoses are based on the medical chart, an interview with the patient and the caregiver, a general medical examination, hematology and blood chemistry tests, and neuroimaging diagnosis if required. A specialist technician of the ReDeGi periodically reviews the medical chart of the cases of dementia notified in each of the 7 hospitals of the HRG and registers the information in a clinical research form containing (1) center identification, date of admission, and clinical history identification number; (2) sociodemographical characteristics; (3) characteristics of the diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition),¹⁸ date of onset of the symptoms, and date of diagnosis; (4) clinical characteristics (date of administration and score of the Mini-Mental State Examination,¹⁹ the Blessed Dementia Rating Scale,²⁰ and the Clinical Dementia Rating (CDR),²¹ family history of dementia, diagnosis of hypertension, diabetes mellitus, dyslipidemia, cerebrovascular adverse events, thyroid disease, depression history, or personal history of psychosis. The collected information of the ReDeGi meets the confidentiality requirements stated by the Spanish legislation.

Drug Consumption Information

The ReDeGi database was linked with the HRG Pharmacy Unit database from the Public Catalan Healthcare Service (PCHS). This database contains all the drugs prescribed by the PCHS professionals that have been dispensed in pharmacies. Patient records were linked using the personal identification code included in their medical chart. All drugs were provided by the PCHS database at 5th level Anatomical Therapeutic Chemical classification system, and benzodiazepines were grouped according to their half-life (short-acting, intermediate-acting, and long-acting).

Data Analysis

A descriptive analysis of the variables was performed using central tendency measures and dispersion for quantitative variables, whereas absolute and relative frequencies were calculated for qualitative variables. The clinical and demographic characteristics between patients with AD and FTLD, and their drug consumption patterns were compared using χ² tests for categorical variables and the Mann-Whitney U test for continuous variables. Normality was checked using Shapiro-Wilk test. Binary logistic regression models were performed to detect the main variables related to AChEI and memantine use in patients with FTLD and AD. Results are expressed as absolute numbers and percentages, means, standard deviations, odd ratios, and 95% confidence intervals (CIs). Statistical tests were considered to be significant with a 2-tailed P value <.05. Processing and analysis of the data were performed using the statistical package SPSS v15.0 for Windows (SPSS, Inc, Chicago, Illinois).

Results

During the period 2007 to 2009, 1894 dementia cases were registered by the ReDeGi in the HRG, of which 57.7% (n = 1092) had AD and 3.4% (n = 64) had FTLD. Of the latter, 79.7% (n = 51) corresponded to the behavioral variant of FTLD, whereas the rest (20.3%, n = 13) were primary progressive aphasia.

The mean age of the patients was 79.4 (standard deviation = 6.9) years, and 62.6% (95% CI: 59.8-65.5) were women. Only 6.8% (95% CI: 5.0-8.0) lived in long-term care residences, and presenile forms accounted for 6.1% (95% CI = 4.6-7.5) of the cases. Regarding severity, 66.9% (95% CI: 64.1-69.6) of the cases were mild (CDR = 1), 24.3% (95% CI: 21.8-26.9) were moderate (CDR = 2), and 8.8% (95% CI: 7.1-10.5) were severe (CDR = 3).

Sociodemographic and clinical characteristics of patients with AD and FTLD are shown in Table 1.

Table 1.

Clinical and Sociodemographic Characteristics of the Patients With Alzheimer’s Disease and Frontotemporal Lobar Degeneration Registered in the Registry of Dementias of Girona

		FTLD (n = 64)
	AD (n = 1092)	bvFTD (n = 51)	PPA (n = 13)
Female gender (n, %)^a	696 (63.7)	20 (39.2)	8 (61.5)
Mean age (SD)^b	79.7 (6.5)	72.3 (9.9)	75.8 (6.3)
Residence in long-term care (n, %)^b	75 (7.2)	0 (0.0)	0 (0.0)
Marital status—married/couple (n, %)^b	502 (48.8)	31 (60.8)	8 (61.5)
CDR (n, %)^a
1	716 (66.0)	39 (79.6)	12 (92.3)
2	270 (24.9)	8 (16.3)	1 (7.7)
3	99 (9.1)	2 (4.1)	0 (0.0)
Mean MMSE (SD)^b	17.3 (5.3)	21.2 (5.6)	19.8 (8.6)
Mean BDRS cognitive (SD)^a	3.5 (1.6)	3.1 (1.4)	2.4 (1.5)
Mean BDRS functional (SD)	0.9 (1.7)	0.7 (1.2)	0.6 (1.0)
Mean BDRS behavior (SD)	2.8 (1.9)	3.7 (2.0)	1.7 (1.6)
Presenile age of onset (n, %)^a	59 (5.4)	11 (21.6)	0 (0.0)
HTA (n, %)	538 (49.7)	20 (39.2)	7 (53.8)
DM (n, %)^a	187 (17.3)	18 (35.3)	1 (7.7)
DPLM (n, %)	293 (27.1)	12 (23.5)	1 (7.7)

Abbreviations: AD, Alzheimer’s disease; CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; MMSE, Mini-Mental State Examination; BDRS, Blessed Dementia Rating Scale; HTA, hypertension; DM, diabetes mellitus; DPLM, dyslipidemia; bvFTD, behavioral variant frontotemporal dementia; SD, standard deviation; PPA, primary progressive aphasia.

^a P < .05 between AD and FTLD.

^b P < .001 between AD and FTLD.

Antidementia drugs were prescribed to 62.9% of the cases with AD and to 43.8% of the cases with FTLD. Specifically, 57.6% and 17.2% of the patients with AD were treated with AChEI and memantine, respectively. In turn, 42.2% and 10.9% of the patients with FTLD used AChEI and memantine, respectively (Table 2).

Table 2.

Central Nervous System Drugs Consumption by the Patients With Alzheimer’s Disease and Frontotemporal Lobar Degeneration Registered in the Registry of Dementias of Girona (ReDeGi)

		FTLD (n = 64)
	AD (n = 1092)	bvFTD (n = 51)	PPA (n = 13)
[N02] Analgesics	656 (60.1)	31 (60.8)	6 (46.2)
[N03] Antiepileptics^a	103 (9.4)	9 (17.6)	2 (15.4)
[N04] Anti-Parkinson	33 (3.0)	1 (2.0)	0 (0.0)
[N05A] Antipsychotics	286 (26.2)	19 (37.3)^b	1 (7.7)^b
N05AD01 Haloperidol	126 (11.5)	5 (9.8)	0 (0.0)
N05AA02 Levomepromazine	14 (1.3)	2 (3.9)	0 (0.0)
N05AX08 Risperidone	131 (12.0)	11 (21.6)	0 (0.0)
N05AH04 Quetiapine	30 (2.7)	4 (7.8)	0 (0.0)
N05AL01 Amisulpride	46 (4.2)	0 (0.0)	1 (7.7)
[N05B] Anxiolytics	445 (40.8)	18 (35.3)	6 (46.2)
[N05C] Hypnotics—sedatives	205 (18.8)	9 (17.6)	0 (0.0)
[N06A] Antidepressants	579 (53.0)	28 (54.9)	6 (46.2)
[N06B] Psychostimulants	137 (12.5)	11 (21.6)	2 (15.4)
[N06D] Antidementia^a	687 (62.9)	24 (47.1)	4 (30.8)
N06DA02 Donepezil^a	350 (32.1)	8 (15.7)	3 (23.1)
N06DA03 Rivastigmine	203 (18.6)	12 (23.5)	0 (0.0)
N06DA04 Galantamine	76 (7.0)	4 (7.8)	0 (0.0)
N06DX01 Memantine	188 (17.2)	6 (11.8)	1 (7.7)

Abbreviations: AD, Alzheimer’s disease; bvFTD, behavioral variant frontotemporal dementia; FTLD, frontotemporal lobar degeneration; PPA, primary progressive aphasia.

^a P < .05 between AD and FTLD.

^b P < .05 between bvFTD and PPA.

Antipsychotics were used in 26.2% of the patients with AD and 31.3% of the patients with FTLD. The use of haloperidol, risperidone, and other antipsychotics with a frequency of use of 2% or more was analyzed and is shown in Table 2.

Anti-Parkinson drugs frequency of use was 3.0% in AD cases and 1.6% in FTLD. Psychostimulants were used by 12.5% of the patients with AD and 20.3% of patients with FTLD. In particular, psychostimulants included methylphenidate, dextroamphetamine, amphetamine, lisdexamfetamine, atomoxetine, modafinil, and armodafinil (Table 2). Anxiolytics were prescribed to 40.8% and 37.5% of the cases with AD and FTLD, respectively. Hypnotics and sedatives were used by 18.8% and 14.1% of the patients with AD and FTLD. Of all patients with AD, 37.4% used intermediate-acting benzodiazepines (alprazolam, bromazepam, ketazolam, lorazepam, lormetazepam, and flunitrazepam), 12.3% used long-acting compounds (diazepam, clobazam, clorazepate, and flurazepam), and only 0.6% consumed short-acting benzodiazepines (bentazepam, midazolam, and triazolam). The patients with FTLD used intermediate-acting benzodiazepines in 26.6% of the cases (alprazolam, bromazepam, ketazolam, lorazepam, lormetazepam, and flunitrazepam), long-acting (diazepam, clobazam, clorazepate, and flurazepam) in 23.4% of the cases, and no patient with FTLD consumed short-acting benzodiazepines (Table 3).

Table 3.

Consumption of Benzodiazepines by the Patients With Alzheimer’s Disease and Frontotemporal Lobar Degeneration Registered in the Registry of Dementias of Girona (ReDeGi)

	AD (n = 1092)	FTLD (n = 64)
	AD (n = 1092)	bvFTD (n = 51)	PPA (n = 13)
Short-acting, n (%)	6 (0.6)	0 (0.0)	0 (0.0)
N05BA91 Bentazepam	1 (0.1)	0 (0.0)	0 (0.0)
N05CD08 Midazolam	4 (0.4)	0 (0.0)	0 (0.0)
N05CD05 Triazolam	1 (0.1)	0 (0.0)	0 (0.0)
Intermediate-acting, n (%)^a	408 (37.4)	14 (27.5)	3 (23.1)
N05BA12 Alprazolam	121 (11.1)	5 (9.8)	2 (15.4)
N05BA08 Bromazepam	23 (2.1)	1 (2.0)	0 (0.0)
N05BA10 Ketazolam	6 (0.5)	0 (0.0)	0 (0.0)
N05BA06 Lorazepam	239 (21.9)	9 (17.6)	2 (15.4)
N05CD06 Lormetazepam	103 (9.4)	4 (7.8)	0 (0.0)
N05CD03 Flunitrazepam	4 (0.4)	0 (0.0)	0 (0.0)
Long-acting, n (%)^b	134 (12.3)^c	11 (21.6)	4 (30.8)
N05BA01 Diazepam^b	53 (4.9)	5 (9.8)	3 (23.1)
N05BA51 Diazepam in association	7 (0.6)	0 (0.0)	0 (0.0)
N05BA09 Clobazam	5 (0.5)	0 (0.0)	0 (0.0)
N05BA05 Clorazepate	63 (5.8)	5 (9.8)	0 (0.0)
N05BA55 Clorazepate in association	11 (0.1)	0 (0.0)	1 (7.7)
N05CD05 Triazolam	1 (0.1)	0 (0.0)	0 (0.0)
N05CD01 Flurazepam	3 (0.3)	1 (2.0)	0 (0.0)

^aTotally 76 AD cases and 6 FTLD cases used 2 different intermediate-acting benzodiazepines; 6 AD cases used 3 different intermediate-acting benzodiazepines.

^b p < .05 between AD and FTLD.

^cSix AD cases used 2 different long-acting benzodiazepines.

Abbreviations: AD, Alzheimer’s disease; bvFTD, behavioral variant frontotemporal dementia; FTLD, frontotemporal lobar degeneration; PPA, primary progressive aphasia.

Antidepressants were prescribed to 53.0% and 53.1% of the patients with AD and FTLD, respectively. Specifically, 36.6% AD cases, and 31.3% FTLD cases used selective serotonin reuptake inhibitors, and 20.0% and 23.4% used tetracyclic antidepressants, respectively (Table 4).

Table 4.

Consumption of Antidepressants by the Patients With Alzheimer’s Disease and Frontotemporal Lobar Degeneration Registered in the Registry of Dementias of Girona (ReDeGi)

	AD (n = 1092)	FTLD (n = 64)
	AD (n = 1092)	bvFTD (n = 51)	PPA (n = 13)
Tricyclic, n (%)^a	27 (2.5)	2 (3.9)	1 (7.7)
N06AA02 Imipramine	3 (0.3)	1 (2.0)	0 (0.0)
N06AA04 Clomipramine	5 (0.5)	1 (2.0)	0 (0.0)
N06AA09 Amitriptyline	18 (1.6)	0 (0.0)	1 (7.7)
N06AA10 Nortriptyline	1 (0.1)	0 (0.0)	0 (0.0)
N06AA12 Doxepin	1 (0.1)	0 (0.0)	0 (0.0)
Tetracyclic, n (%)^b	218 (20.0)	15 (29.4)^c	0 (0.0)^c
N06AA21 Maprotiline	1 (0.1)	0 (0.0)	0 (0.0)
N06AX03 Mianserin	4 (0.4)	0 (0.0)	0 (0.0)
N06AX05 Trazodone	190 (17.4)	14 (27.5)	0 (0.0)
N06AX11 Mirtazapine	31 (2.8)	1 (2.0)	0 (0.0)
SSRI, n (%)^d,e	396 (36.3)	15 (29.4)	5 (38.5)
N06AB03 Fluoxetine	50 (4.6)	4 (7.8)	2 (15.4)
N06AB04 Citalopram^c	179 (16.4)	4 (7.8)	1 (7.7)
N06AB05 Paroxetine	97 (8.9)	1 (2.0)	1 (7.7)
N06AB06 Sertraline	56 (5.1)	5 (9.8)	2 (15.4)
N06AB08 Fluvoxamine	3 (0.3)	0 (0.0)	0 (0.0)
N06AB10 Escitalopram	57 (5.2)	3 (5.9)	1 (7.7)
SNRI, n (%)^d
N06AX18 Reboxetine	1 (0.1)	0 (0.0)	0 (0.0)
SSNRI, n (%)^d,f	62 (5.7)	6 (11.8)	0 (0.0)
N06AX16 Venlafaxine	45 (4.1)	5 (9.8)	0 (0.0)
N06AX21 Duloxetine	20 (1.8)	1 (2.0)	0 (0.0)

Abbreviations: AD, Alzheimer’s disease; bvFTD, behavioral variant frontotemporal dementia; FTLD, frontotemporal lobar degeneration; PPA, primary progressive aphasia; SSRIs, selective serotonin reuptake inhibitors; SNRIs, selective noradrenalin reuptake inhibitors; SSNRIs, selective serotonin and noradrenalin reuptake inhibitors.

^a One AD case used 2 different tricyclic antidepressants.

^bEight AD cases used 2 different tetracyclic antidepressants.

^c P < .05 between bvFTD and PPA.

^d P < .05 between AD and FTLD.

^eForty-six AD cases and 4 FTLD used 2 different SSRIs.

^fThree AD cases used 2 different SSNRIs.

Multiple regression models using all available sociodemographic and clinical variables were performed in order to detect any association with AChEI and memantine consumption, both in FTLD and AD. There were no variables related to antidementia drug consumption.

Discussion

Despite the lack of efficacy of antidementia drugs, and even though they are not indicated in the treatment of FTLD, according to our results, approximately half of the patients were prescribed this medication. Our study is in agreement with a population study performed in California,²² which showed the same percentage of patients with AD and FTLD taking any antidementia drug (donepezil, galantamine, rivastigmine, or memantine). Nevertheless, in our population, patients with AD most frequently used donepezil, whereas FTLD cases used either donepezil or rivastigmine.

Moreover, unlike in the American study, our patients were more frequently treated with CNS drugs, specially anxiolytics (37.5% vs 6.8%), antidepressants (53.1% vs 43.2%), and antipsychotics (31.3% vs 4.5%).

In most of the cases, the usefulness of CNS drugs to help control behavioral and psychological symptoms in FTLD is controversial. While in some studies, fluvoxamine and paroxetine significantly improved behavior, results by other authors indicated poor benefit of fluoxetine, sertraline, and lithium carbonate. In several studies, the use of trazodone improved behavioral but not cognitive symptoms. Neuroleptics in general, and risperidone as the most common antipsychotic used, do not improve behavior or cognition.^23,24 Despite this, as much as 31.3% of the patients with DLFT were prescribed an antipsychotic, and of them, 55% used risperidone. This extensive use of neuroleptics should be seriously reconsidered, especially if taking into account their serious adverse effects such as cognitive impairment, Parkinsonism, and increased risk of stroke.^25
–27

The use of psychostimulants was low, both in our study and in the American population study by Bei Hu et al,²² and both in AD and FTLD cases. However, in our population, 20.2% of the cases with FTLD were prescribed a psychostimulant. The most frequently used psychostimulant was methylphenidate, even when it does not improve cognitive symptoms, and the extent of its efficacy is uncertain.^23,28

No differences were detected between treated and not treated FTLD patients with antidementia drugs (AChEI and/or memantine). Age, sex, residence, education, risk factors, clinical history and clinical symptomatology, and other CNS drugs consumption were variables used in the multivariate analysis that yielded no associations. This leads us to think, in agreement with Bei Hu et al,²² that maybe, these drugs are used only because of medical uncertainties in making a precise diagnosis in the first stages of the disease, and/or due to the need to offer a pharmacological treatment when the patient or the caregiver asks for it. Finally, it might also be due to a general tendency to medicate all patients with dementia.

Current knowledge clearly shows that patients with FTLD have deficiencies in dopaminergic and serotoninergic neurotransmission systems but have no alteration in acetylcholine system.²⁹ The low prevalence and high clinical complexity of FTLD hinder clinical trials, and the scarce studies performed with drugs authorized to treat AD, revealed no benefits when used in FTLD.^{12,13,30

–33}

Some limitations must be considered when interpreting the results obtained in this study. Information on the dosages prescribed would be required, as well as the duration of the treatment, to calculate defined daily doses for each drug. In addition, the lack of information on adherence, or treatment withdrawal, might influence the interpretation of the results. Finally, we do not have information on eventual comorbidities in the registered cases, and we cannot definitely assert that all CNS medications were used to treat dementia-related behaviors.

In summary, the existing discrepancy regarding clinical practice and the recommendations based upon clinical evidence warrant further multicentric studies aiming at finding the best means to treat patients with FTLD.

Footnotes

Acknowledgments

The ReDeGi is founded by the Health Region of Girona from the Department of Health of the Generalitat de Catalunya (Spain).

Co-investigators

Department of Neurology, Hospital Universitari Josep Trueta: Mar Castellanos, PhD; David Genís Batlle, MD; Jordi Gich, BPsych; Rosa Meléndez, MD; Albert Molins, MD; Lluís Ramió, MD; Joaquín Serena, PhD; Yolanda Silva, PhD. Dementia Unit, Hospital Santa Caterina: Marta Hernández, BPsych; Saioa Lejarreta, MD; Manuela Lozano, BPsych; Immaculada Pericot, PhD; Joan Vilalta-Franch, PhD; Antoni Turon Estrada, PhD; Josefa Turbau, MD; Jordi Llinás, BPsych; Secundino López-Pousa, PhD. Dementia Unit, Hospital de Palamós: Elisabet Alsina, BSw; Rosa de Eugenio, MD; Erélido Hernández, MD; Margarita Flaqué, BPsych. Neurology Department, Hospital de Figueres: Olga Carmona, MD; Marta Cullell, BPsych; Teresa Osuna, MD; Maria Aguirregomozcorta, MD; M^a del Mar Fernández, MD. Neurology and Geriatrics Departments, Hospital d’Olot: Josep Bisbe, MD; Marta Linares, BPsych; Fabian Marquez Daniel, MD; Natalia Vallmajó, MD. Neurology and Geriatrics Departments, Hospital de Blanes: Fernando Espada, MD; Teresa Casadevall, MD; Héctor Perkal, MD; Marta Viñas, MD. Neurology Department; Hospital de Campdevánol: Isabel Casas, BPsych; Josefa Turbau, MD; Josep M^a Cuy, MD; Anna Manzano, MD. Pharmacy Unit, Healh Region of Girona: Anna Maria Roig, BPharm; Joan Coromina, BPharm; Mónica Palacios Soto, BPharm.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Petersen

. Mild cognitive impairment: transition between aging and Alzheimer’s disease. Neurologia. 2000;15(3):93–101.

Hachinski

. Shifts in thinking about dementia. JAMA. 2008;300:2172–2173.

Braak

. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239–259.

Braak

de Vos

Jansen

Bratzke

Braak

. Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Prog Brain Res. 1998;117:267–285.

Barker

Luis

Kashuba

Relative frequencies of Alzheimer disease, lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–212.

McKhann

Albert

Grossman

Miller

Dickson

Trojanowski

. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol. 2001;58(1):1803–1809.

Toribio-Díaz

Morera-Guitart

. Clasificación clínica y biomolecular de las demencias frontotemporales. Rev Neurol. 2008;47(11):588–598.

Mega

Cummings

. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6(4):358–370.

Ratnavalli

Brayne

Dawson

Hodges

. La prevalencia de la demencia frontotemporal. Neurología. 2002;58(11):1615–1621.

10.

Trojanowski

Dickson

. Update on the neuropathological diagnosis of frontotemporal dementia. J Neuropathol Exp Neurol. 2001;60(12):1123–1126.

11.

Massoud

Léger

. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–588.

12.

Larner

. Cholinesterase inhibitors: beyond Alzheimer’s disease. Expert Rev Neurother. 2010;10(11):1699–1705.

13.

O'Brien

Burns

; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997–1019.

14.

German

Armstrong

Birkhead

. Surveillance coordination Group. Updated guidelines for evaluating public health surveillance systems. MMWR Recomm Rep. 2001;50(RR-13):1–35.

15.

Garre-Olmo

Flaqué

Gich

Clinical registry of dementia based on the principle of epidemiological surveillance. BMC Neurol. 2009;9:5.

16.

Garre-Olmo

Genis-Batlle

del Mar Fernandez

Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75(14):1249–1255.

17.

López-Pousa

Garre-Olmo

Monserrat-Vila

Propuesta para un registro clínico de demencias. Rev Neurol. 2006;43(1):32–38.

18.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

19.

Folstein

McHugh

. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.

20.

Blessed

Tomilson

Roth

. The association between quantitative measures of dementia, and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797–811.

21.

Morris

. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414.

22.

Bei

Ross

Neuhaus

Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2010;25(2):128–133.

23.

Kaye

Petrovic-Poljak

Verhoeff

Freedman

. Frontotemporal dementia and pharmacologic interventions. J Neuropsychiatry Clin Neurosci. 2010;22(1):19–29.

24.

Portugal Mda

Marinho

Laks

. Tratamiento farmacológico de la frontotemporal la degeneración lobar: revisión sistemática. Rev Bras Psiquiatr. 2011;33(1):81–90.

25.

Wooltorton

. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J. 2002;167(11):1269–1270.

26.

Wooltorton

. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004;170(9):1395.

27.

Vilalta-Franch

López-Pousa

Garre-Olmo

Turon-Estrada

Pericot-Nierga

. Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos. Rev Neurol. 2008;46(3):129–134.

28.

Dolder

Davis

McKinsey

. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44(10):1624–1632.

29.

Huey

Putnam

Grafman

. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17–22.

30.

Moretti

Torre

Antonello

Cattaruzza

Cazzato

Bava

. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931–937.

31.

Lampl

Sadeh

Lorberboym

. Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann Pharmacother. 2004;38(11):1967–1968.

32.

Mendez

Shapira

. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84–87.

33.

Kertesz

Morlog

Light

Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178–185.

Use of Antidementia Drugs in Frontotemporal Lobar Degeneration

Abstract

Keywords

Introduction

Methods

Design, Geographical Area of Reference, and Study Population

Registry Procedure and Registered Variables

Drug Consumption Information

Data Analysis

Results

Discussion

Footnotes

Acknowledgments

Co-investigators

Declaration of Conflicting Interests

Funding

References